Trial Profile
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 20 May 2021 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 1 Apr 2021 to 1 May 2021.
- 27 Apr 2021 Planned primary completion date changed from 1 Apr 2021 to 1 May 2021.